Ultra-LEAF™ Purified anti-mouse IFN-γ Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

E. coli-expressed, recombinant mouse IFN-γ

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ELISA Capture, ELISPOT Capture - Quality tested
CyTOF® - Verified
Neut, ICFC, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISPOT Capture, the suggested use of this antibody is 1 - 4 µg/ml. For ELISA capture applications, a concentration range of 0.5-2.0 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IFN-γ recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA^1-4,11,14 or ELISPOT⁵ Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry^7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization^1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections^6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

Product Citations

1. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
2. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
3. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
4. Cui P, et al. 2023. J Neuroinflammation. 20:63. PubMed
5. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
6. Chinchalongporn W, et al. 2023. JVS Vasc Sci. 100129:4. PubMed
7. Ogbechi J, et al. 2022. Front Immunol. 13:1001956. PubMed
8. Parashar K, et al. 2020. Immun Inflamm Dis. 0.696527778. PubMed
9. Amir M, et al. 2018. Cell Rep. 25:3733. PubMed
10. Burke TP, et al. 2020. Nat Microbiol. 0.686111111. PubMed
11. LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed
12. Zhao K, et al. 2022. Adv Sci (Weinh). 9:e2103838. PubMed
13. Fidler TP, et al. 2021. Nature. 592:296. PubMed
14. Mock JR, et al. 2020. Am J Respir Cell Mol Biol. 63:464. PubMed
15. Li N, et al. 2021. iScience. 24:103163. PubMed
16. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
17. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
18. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
19. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
20. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
21. Bier J, et al. 2021. Front Immunol. 12:671258. PubMed
22. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
23. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed

RRID

AB_2616676 (BioLegend Cat. No. 505858)
AB_2616676 (BioLegend Cat. No. 505848)
AB_2616676 (BioLegend Cat. No. 505857)
AB_2616676 (BioLegend Cat. No. 505833)
AB_2616676 (BioLegend Cat. No. 505834)
AB_2616676 (BioLegend Cat. No. 505847)

Antigen Details

Structure

Cytokine; dimer; 40-80 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs

Cell Sources

CD8⁺ and CD4⁺ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone

Gene ID

15978 View all products for this Gene ID

UniProt

View information about IFN-gamma on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis